Venezuela will not authorise AstraZeneca COVID-19 vaccine due to ‘effects on patients’

AstraZeneca plc is a British-Swedish multinational pharmaceutical and biotechnology company with its headquarters in Cambridge, England. A nurse holds a dose of AstraZeneca vaccine before administering it to a tourist resort employee north of Port Louis, Mauritius, Wednesday Feb. 10, 2021. Three tourist hotels have been selected as vaccination centers as the Indian ocean island kicks its COVID-19 vaccination campaign. (Sumeet Mudhoo/L’express Maurice via AP)
03/15/2021
Share on facebook
Share on twitter
Share on linkedin
Share on reddit
Share on pinterest
Share on whatsapp
Share on email

CARACAS (Reuters) – Venezuela will not authorise AstraZeneca’s COVID-19 vaccine, Vice President Delcy Rodriguez said on Monday, citing unspecified “effects on patients.”

Rodriguez’ comments came after several European countries paused inoculations using the vaccine following reports of blood coagulation in recipients. Other countries, including Canada and Australia, have continued to recommend its use.

Venezuela has so far used Russia’s Sputnik V and China’s Sinopharm in its vaccination programme.

The government had been in talks with political opposition – recognised as the South American nation’s legitimate interlocutors by many Western countries – over a possible deal to participate in the World Health Organization’s (WHO) Covax initiative, which provides vaccines to poor countries.

While no deal has been reached so far, AstraZeneca supplies one of the main vaccines used in the Covax initiative.

Rodriguez also said she had met with a representative of the Pan-American Health Organization to reiterate the government’s demand that Britain release gold frozen in Venezuela’s accounts in the country to facilitate payments for Covax vaccines.

(Reporting by Vivian Sequera in Caracas; Writing by Luc Cohen; Editing by Kim Coghill and Kenneth Maxwell)

Become an INSPADES.NEWS Journalist. Submit your story here.

Leave a Reply